https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-20 / J Immunother Cancer 2016;4:92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-20 / J Immunother Cancer 2016;4:922016-12-20 00:00:002019-02-15 08:53:12The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-07 / Cancers (Basel) 2016 Jul;8(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-07 / Cancers (Basel) 2016 Jul;8(7)2016-07-07 00:00:002019-02-15 08:53:09A Perspective of Immunotherapy for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / BJU Int. 2016 10;118(4):506-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / BJU Int. 2016 10;118(4):506-142016-06-03 00:00:002019-02-15 08:52:00Recent advances in immuno-oncology and its application to urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-522016-05-24 00:00:002016-05-24 00:00:00Oncolytic virotherapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra272016-03-02 00:00:002022-09-29 14:06:28Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)2015-05-30 00:00:002015-05-30 00:00:00Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-352015-03-17 00:00:002019-02-15 08:53:06Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-29 / Oncol. Rep. 2015 Apr;33(4):1585-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-29 / Oncol. Rep. 2015 Apr;33(4):1585-922015-01-29 00:00:002019-02-15 08:52:44A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-07 / Urol. Oncol. 2015 May;33(5):245-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-07 / Urol. Oncol. 2015 May;33(5):245-602015-01-07 00:00:002019-02-15 08:53:08Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
